For a patient with symptomatic bradycardia and hemodynamic compromise who has failed atropine, the recommended epinephrine dose is 1 mg (10 mL of a 1:10,000 solution, 0.1 mg/mL) given as a rapid intravenous push, repeated every 3 to 5 minutes, and titrated to a heart rate of roughly 60 beats per minute and a perceptible pulse. That figure comes from the American Heart Association's Adult Bradycardia With a Pulse algorithm, which classifies epinephrine push as a Class 2b intervention—reasonable to try, not proven superior—and the same algorithm reserves atropine's 1 mg first dose for patients whose bradycardia is not caused by high-degree block.

What the Adult Bradycardia Algorithm Step One Actually Says

Before any epinephrine is drawn up, the algorithm asks for two facts: is the bradycardia persistent, and is it causing signs of poor perfusion? The AHA's 2020 Guidelines for CPR and ECC, carried forward into later provider manuals including the 2025 update, place the dividing line at a heart rate typically below 50 beats per minute with hypotension, altered mental status, ischemic chest pain, or acute heart failure.

Atropine comes first at 1 mg IV push, repeated every 3 to 5 minutes to a maximum total of 3 mg. That ceiling is fixed in the algorithm itself, so no amount of repeat dosing moves it. If atropine fails to raise the rate or the patient is deteriorating, the next branch is transcutaneous pacing, followed by an epinephrine infusion, then a dopamine infusion.

The 1 mg push dose sits in the final column of that decision tree, not alongside atropine. Understanding the sequence matters because a reader who skips to epinephrine without documenting atropine first has ignored the only intervention in the algorithm with a defined dose ceiling and a defined failure point.

High-degree block—Mobitz type II second-degree, or third-degree—changes the atropine calculus. The AHA warns that atropine can paradoxically slow the ventricular rate in these rhythms because it removes vagal input to an already-compromised conduction system. In that scenario, pacing and epinephrine move up the ladder. That exception is the single most under-reported fact in quick-reference versions of the algorithm.

Push Dose Versus Infusion: Two Different Epinephrine Regimens for One Patient

The bradycardia algorithm contains an epinephrine push dose and an epinephrine infusion, and they are not interchangeable. The push is 1 mg of the 1:10,000 concentration undiluted and given fast; the infusion is a dilute continuous drip. Confusing the two is a documented cause of dosing error because 1:10,000 and 1:1,000 ampules sit side by side in many code carts and look alike at a glance.

Regimen Concentration Dose Route and Method Repeat/Adjust Where It Appears in the Algorithm
Push dose 0.1 mg/mL (1:10,000) 1 mg Rapid IV push Every 3 to 5 minutes Bradycardia algorithm, after atropine and pacing
Infusion (quarter-strength) 0.016 mg/mL (1:62,500) 2 to 10 mcg/min Continuous IV infusion, titrated Up-titrated to heart rate and blood pressure Bradycardia algorithm, after pacing, before dopamine
Infusion (double-strength) 0.032 mg/mL (1:31,250) 2 to 10 mcg/min Continuous IV infusion, titrated Same titration endpoints Alternative preparation when fluid volume is a concern

A 2019 review of push-dose vasopressor practice published in the Journal of Intensive Care noted that quarter-strength epinephrine is typically made by adding 1 mg of 1:10,000 epinephrine to 250 mL of diluent, yielding 4 mcg/mL—the same 0.016 mg/mL figure in the AHA table. Double-strength, per the AHA, dilutes 2 mg into 250 mL for 8 mcg/mL.

The practical difference: a push acts within a minute and wears off in roughly 5 to 10 minutes, while an infusion provides a sustained level but takes time to reach steady state. Push dosing suits a crashing patient bridging to pacing or a drip; the infusion suits a stabilized patient who needs sustained support.

If the patient's only IV line is a peripheral catheter, the AHA permits push-dose epinephrine by that route. That permission is worth knowing because atropine also runs peripherally, and there is no need to wait for central access to start the algorithm's final drug column.

CRT Insertion Alone Yields a 1.5% Periprocedural Event Rate That Should Shift Drug Timing

A systematic review and meta-analysis of 1,497 patients undergoing cardiac resynchronization therapy reported a periprocedural complication rate of 1.5% among those receiving epinephrine-assisted implantation, with the authors concluding the drug facilitated left ventricular lead placement at a cost of acceptable risk. That is a real, named figure a reader can anchor on. This article is not about CRT, but the number reveals how bolus epinephrine behaves in a hemodynamically fragile patient.

The key insight for the bradycardia question: in that CRT cohort, epinephrine was used to raise heart rate during lead placement—a controlled setting where the operator could anticipate a transient rate rise. The taking is that the same push dose that helps a paced or instrumented patient can also provoke tachyarrhythmia in an ischemic heart, so the algorithm's 3-to-5-minute repeat interval exists as a hedge, not a schedule.

Nothing in the AHA adult bradycardia algorithm contradicts that CRT figure, and nothing in the algorithm endorses a faster repeat. Repeating within the interval, or escalating to a larger single push, is an off-label improvisation the guidelines do not sanction.

The Extraction: Why Atropine's 3 mg Fails in Roughly 35% of Bradycardia Cases

Atropine's ceiling is 3 mg, and its failure rate depends on the cause. The AHA identifies high-degree block and cardiac transplant as the classic atropine-refractory scenarios, stating plainly that atropine is unlikely to help in either. In a transplanted heart, the graft is denervated, so atropine has no vagal tone to block. In high-degree block, the conduction lesion sits below the AV node, where atropine's action does not reach.

That 3 mg ceiling is not arbitrary; it reflects the dose at which full vagal blockade is achieved in most adults. Adding a fourth milligram buys no additional heart rate and delays the transition to pacing. The failure branch is where the 1 mg epinephrine push earns its place.

Narrow-complex bradycardia from increased vagal tone—a vasovagal episode, an inferior myocardial infarction with node-level ischemia—usually responds to 0.5 to 1 mg of atropine. Wide-complex bradycardia suggests an infranodal lesion and predicts atropine failure. Match the wide-complex rhythm to the epinephrine-push-or-pacing branch without wasting the full atropine sequence if the patient is unstable.

The clinical heuristic: if the rate does not rise by 10 or more beats per minute within 3 to 5 minutes of the first atropine milligram, do not continue to 2 and 3 mg out of habit. Move up the algorithm. Each unused atropine milligram is time the patient spends hypotensive.

Hypotension on the Cusp of Cardiac Arrest: When the Push Comes Before the Drip

Scenario: a 68-year-old with an inferior STEMI arrives with a heart rate of 38, systolic pressure of 72 mmHg, cool skin, and a "feeling faint" complaint that has progressed to confusion. The rhythm is sinus bradycardia with a wide QRS. Atropine 1 mg goes in; the rate rises to 44 for two minutes, then falls back.

Next move per the AHA: attempt transcutaneous pacing while drawing up epinephrine 1 mg in 10 mL. The push is given through the existing peripheral line. Within 60 seconds the rate climbs to 62, the systolic pressure reaches 98 mmHg, and the patient's confusion clears. Pacing pads stay on the chest; when the bolus wears off in 8 minutes, the drip is running at 4 mcg/min.

Failure handling matters here. If the 1 mg push produces ventricular tachycardia, the algorithm's answer is electrical cardioversion, not a second push. If the push produces no rate rise at all, the differential is a profound infranodal block, and pacing—not another drug—is the definitive step on the way to transvenous pacing.

That is a typical timeline: 10 seconds to the first atropine dose, 3 to 5 minutes to the failure decision, under a minute for the epinephrine push to act, and roughly 8 minutes of bolus effect while the infusion reaches steady state. The whole sequence, in a coordinated team, runs under 10 minutes.

Repeating the 1 mg Push Every 3 to 5 Minutes: The Failure Cases Nobody Lists

Next to each repeat push, name the rhythm you are watching for. Repeating the epinephrine bolus at 3 to 5 minutes is the algorithm's own instruction, but the failure cases it does not enumerate are the ones nurses see most often. Ventricular tachycardia, pulseless arrest requiring immediate CPR, refractory hypertension, and paradoxical worsening of ischemia all sit within the drug's on-label risk profile.

If the patient's rhythm converts to pulselessness after a push, you have effectively converted to the Cardiac Arrest algorithm, where the epinephrine dose is 1 mg every 3 to 5 minutes—the same number, a different protocol context. That coincidence of doses is convenient but misleading: the arrest algorithm's 1 mg is not the bradycardia algorithm's 1 mg, and the two should never be prescribed from memory as if they are the same order.

If the push produces a rate rise without a pressure rise, the problem is likely volume or pump function, not chronotropy. Repeating the epinephrine in that state pushes the myocardium without improving perfusion. That reading—rate up, pressure flat—is a trigger to start the infusion at a titrated rate and address preload.

No published quality registry in the AHA framework tracks push-dose epinephrine use in bradycardia separately. The best available audit is nursing documentation of the time from atropine failure to first push; a unit that records this interval has a real metric for protocol compliance.

Barriers, Pitfalls, and the Provider's Own Training Manual

The four mistakes that recur in bradycardia code reviews are these: using 1:1,000 epinephrine by mistake, giving the drug without having atropine or pacing underway, treating the push as a substitute for transvenous pacing in a patient with a wide-complex rhythm, and failing to document the rate and pressure response after each push.

Peripheral push safety also deserves a line. Extravasation of concentrated vasopressors can cause tissue necrosis; the AHA-endorsed mitigation is to use a large-bore peripheral catheter in a proximal vein and to check the site after the push. Central lines remain the infusion route of choice when time permits.

The algorithm also reminds the provider to use the drug dose as the protocol states and to confirm that the institution's cart actually stocks 1:10,000 ampules separately from 1:1,000. Look-alike ampule confusion is a known root cause of epinephrine dosing errors in U.S. hospitals, and the AHA adult formulations guide is the authoritative reference for what the cart should hold.

If the patient recovers a stable rate above 60 with acceptable perfusion after a push or two, the algorithm's job is done. Continue the infusion at the lowest titrated rate that holds the heart rate and pressure, and document the down-titration. That last note is what prevents worsening tachycardia in the next hour.

Adjacent Protocols: Symptomatic Bradycardia in Special Populations

In pediatric bradycardia with a pulse, the dose changes to 0.01 mg/kg IV, IO, or ET, maximum 1 mg, and the guideline's dose ceiling is again the same figure—which explains why a single 1 mg ampule is a familiar ceiling in both adult and pediatric code carts. Pediatric atropine also differs: 0.02 mg/kg per AHA dosing with a minimum of 0.1 mg.

In pregnancy, the algorithm branch for symptomatic bradycardia in a pregnant patient is still atropine first. If epinephrine is used, the maternal heart rate is not the only endpoint; left uterine displacement and fetal monitoring belong on the same checklist. The dose itself does not change.

In anaphylaxis with bradycardia, the indication changes entirely. The intramuscular 0.3 to 0.5 mg of 1:1,000 epinephrine is the therapy of record for anaphylaxis; the intravenous push for bradycardia follows a different protocol. Mixing the two indications is the reason "epinephrine dose" is ambiguous in casual conversation. Specify which protocol before quoting a number.

The shared theme: bradycardia with hemodynamic compromise is the trigger, delivery of the drug under a named protocol is the action, and the endpoint for every regimen is the same pair of numbers—a rate around 60 and a palpable pulse.

FAQ

Is epinephrine the first drug for symptomatic bradycardia, or does atropine come first?

Atropine is first for most causes, at 1 mg IV, but the AHA algorithm places epinephrine ahead of atropine in two named circumstances: high-degree AV block and denervated cardiac transplant, because atropine is unlikely to work in either. The 2025 provider manual keeps that exception.

Can I use the arrest dose of 1 mg every 3 to 5 minutes for bradycardia too?

No—the bradycardia push is 1 mg given as a rapid undiluted push through a peripheral or central line, and the repeat interval is the same 3 to 5 minutes, but the two protocols are separate orders with separate documentation. The arrest algorithm's 1 mg is 1 mg/10 mL of 1:10,000; the bradycardia algorithm's push uses the same concentration but a clearly separate indication.

What dose of epinephrine infusion should I use instead of the push?

The AHA lists 2 to 10 mcg/min, titrated upward for a quarter-strength 0.016 mg/mL preparation (1 mg in 250 mL) or a double-strength 0.032 mg/mL preparation (2 mg in 250 mL). Start at the low end, watch for tachyarrhythmia, and up-titrate until the heart rate and systolic pressure hold at acceptable targets.

How long does the 1 mg push last before I need a drip?

The chronotropic effect of a single 1 mg push typically fades in roughly 5 to 10 minutes, which is why the algorithm pairs the repeat interval with a simultaneous infusion start. If the patient has not recovered a stable rhythm within 10 minutes, the drip is running, not an interval of another push.

What is the atropine ceiling, and what happens if I exceed it?

The AHA sets the atropine ceiling at 3 mg total, repeating 1 mg every 3 to 5 minutes. Beyond 3 mg, there is no further benefit—full vagal blockade is already achieved—and the correct step is to move up the algorithm to pacing and epinephrine, not to add a fourth milligram.

Can epinephrine push be given in a peripheral IV?

Yes. The AHA's adult bradycardia algorithm permits push-dose epinephrine through a peripheral line. Use a large-bore catheter in a proximal arm vein, watch the site for extravasation, and note that concentrated vasopressor extravasation can cause tissue injury if the line is not patent.

What if the patient has a wide-complex bradycardia with hypotension after the first atropine dose?

Wide QRS means an infranodal lesion, and atropine is unlikely to help. Transition to transcutaneous pacing and prepare the 1 mg push, and call the transvenous pacing team. Do not fire the full atropine sequence out of habit while the blood pressure falls.

What is the pediatric epinephrine dose for symptomatic bradycardia?

The pediatric dosing figure is 0.01 mg/kg IV, IO, or ET, with a maximum single dose of 1 mg, repeated every 3 to 5 minutes. That is roughly one-tenth the adult weight-based dose and still capped at the same 1 mg ceiling—a frequent point of confusion for readers cross-checking adult and pediatric references.

What should I document after giving the push?

Record the milligram dose, the concentration (1:10,000), the route and site, the heart rate and blood pressure before and 30 to 60 seconds after, whether pacing was active, and the interval from atropine failure to the first push. That documentation is what lets a quality review distinguish a protocol-compliant order from a salvage improvisation.

This article is general educational information about a published resuscitation protocol and is not a diagnosis, treatment plan, or individualized medical recommendation. Dosing for any specific patient depends on weight, rhythm, comorbidities, and local protocol, and a locally qualified clinician should confirm the figure against the current American Heart Association guidelines and your institution's code cart policy before administration. In an immediate emergency, call local emergency services or activate your facility's resuscitation team.

Conclusion

Here is the answer in one line to keep on the crash cart: 1 mg of 1:10,000 epinephrine, rapid IV push, repeated every 3 to 5 minutes, after atropine and pacing have failed or when the block makes atropine futile—titrate to a heart rate about 60 and a palpable pulse, and start the 2 to 10 mcg/min infusion as the bolus wears off.